Zealand Pharma A/S — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

3 Recruiting

8 Completed trials

16 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase I (Other)

Phase III: 5 Phase II: 1 Phase I: 1 Phase I (Other): 4

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Short-bowel syndrome 4 Obesity 2 Overweight 2 Weight control 1

Top IMPs

GLEPAGLUTIDE 4 DASIGLUCAGON 1 PETRELINTIDE 1

All trials

11 total

EASE SBS 5 (Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS) Recruiting

2024-512486-14-00 Phase III 14 countries GLEPAGLUTIDE
PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION Recruiting

2025-523641-10-00 Phase I (Other) 2 countries
Single and multiple ascending dose of ZP9830 in healthy participants Recruiting

2023-509929-51-00 Phase I 1 country
A trial to assess the long-term safety and effectiveness of glepaglutide in patients with short bowel syndrome who have been previously trea… Ended

2025-520775-81-00 Phase III 4 countries GLEPAGLUTIDE
Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2 Ended

2025-520598-38-00 Phase I (Other) 1 country
A clinical research study investigating how the body processes the new compound petrelintide in people with kidney problems Ended

2024-518124-77-00 Phase I (Other) 1 country
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide Ended

2024-516901-21-00 Phase I (Other) 1 country
Once-weekly petrelintide versus placebo for obesity or overweight with comorbidities Ended

2024-512549-18-00 Phase II 2 countries PETRELINTIDE
EASE SBS 3 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome (SBS) Ended

2024-513373-43-00 Phase III 6 countries GLEPAGLUTIDE
An extension study of Dasiglucagon in children with CHI Ended

2024-514007-34-00 Phase III 1 country DASIGLUCAGON
EASE SBS 2 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome) (SBS) Ended

2024-513374-22-00 Phase III 5 countries GLEPAGLUTIDE

Showing 1–11 of 11 trials

← All sponsors A–Z